Skip to main content

3 Result(s)

within D F McDermott Remove this filter

and

  1. Article

    Open Access

    Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

    Prognostic scoring systems are used to estimate the risk of mortality from metastatic renal cell carcinoma (mRCC). Outcomes from different therapies may vary within each risk group. These survival algorithms h...

    M. Fishman, J. P. Dutcher, J. I. Clark, A. Alva… in Journal for ImmunoTherapy of Cancer (2019)

    Download PDF (734 KB) View Article

  2. Article

    Open Access

    Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients

    Several reports suggest that vascular endothelial growth factor (VEGF)-targeted therapy in metastatic renal cell carcinoma (mRCC) may be more toxic in Asian vs non-Asian populations. Comparative efficacy of these...

    Y Wang, T K Choueiri, J-L Lee, M-H Tan, S Y Rha, S A North… in British Journal of Cancer (2014)

    Download PDF (261 KB) View Article

  3. Article

    Open Access

    Sunitinib in combination with gemcitabine for advanced solid tumours: a phase I dose-finding study

    This phase I, dose-finding study determined the maximum tolerated dose (MTD), safety, and pharmacokinetics of sunitinib plus gemcitabine in patients with advanced solid tumours.

    M D Michaelson, A X Zhu, D P Ryan, D F McDermott, G I Shapiro… in British Journal of Cancer (2013)

    Download PDF (251 KB) View Article